KNOWLEDGE PORTAL
on innovation and access to medicines

Fair Medicine's mission is to "ensure access to safe, effective and affordable medicines for all those in need, now and in the future. To accomplish that, Fair Medicine introduces a new business model for the development of pharmaceuticals. The pillars of our model: delivery of affordable pharmaceuticals and thus maximum availability, transparency about the development costs and price structures, [and] social responsible and acceptable return on investment for all parties involved…Fair Medicine is about sharing and working together from start to end of the development process. By doing so, development time and costs are reduced. At the same time, products are reasonably priced based on the development costs and with a socially acceptable yield” (Fair Medicine, n.d.).

FIND is a “global non-profit connecting countries and communities, funders, decisionmakers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems…We are working to ensure equitable access to reliable diagnosis around the world” (FIND, n.d.).

Fiocruz’s mission is to “produce, disseminate and share knowledge and technologies aimed at the strengthening and consolidation of the Unified Health System (SUS) and contribute to the promotion of health and quality of life of the population. Besides the reduction of social inequalities and the national dynamics of innovation, with the defense of the right to health and full citizenship as central values” (Fiocruz, n.d.).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S. F1000Research 2021, 10:190).

“Global Access Diagnostics (GADx) is a leading developer of lateral flow and rapid diagnostic technologies, products and services, offering a full suite of services from concept to validation to manufacturing at flexible volumes…GADx was formed by the acquisition of two companies, Mologic and Global Access Diagnostics, by a consortium of social impact investors called Global Access Health. As part of this transition, GADx became a social enterprise, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world” (GADx, n.d.).

“The Global Health Innovative Technology Fund (GHIT) was established to solve the challenges associated with drug development for infectious diseases and achieving Universal Health Coverage under the Sustainable Development Goals. GHIT secures funds for product development through international public–private partnerships and invests in open innovation, drawing on Japan's scientific and pharmaceutical capabilities combined with overseas resources and networks to create life saving tools. GHIT links Japanese and overseas institutions involved in global health R&D, including governments, private companies, foundations, nongovernmental organizations and nonprofit organizations, and United Nations agencies, and encourages dialogue on product development, access, and delivery” (GHIT Fund, n.d.).

“The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded international collaboration facilitating the evaluation of vaccines to prevent HIV/AIDS. The HVTN helps advance the fields of vaccinology, social and behavioral sciences, statistics, and immunology, as well as tuberculosis and COVID-19 vaccines…The HVTN’s mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally” (HVTN, n.d.).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S. F1000Research 2021, 10:190).

"Finch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. [...] Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation." (https://www.biospace.com/employer/548448/finch-therapeutics/)

“The ANRS's mission is to evaluate, stimulate, coordinate, and fund research on AIDS and on human retroviral infections, in collaboration with all organizations that participate in biological and medical research in France, in particular, the CNRS, Inserm, Institut Pasteur, universities, and hospitals… The research supported by the ANRS in resource-limited countries is designed to underpin national public health policies'' (ARNS, n.d.).

This organization was included for its participation in non profit R&D for Neglected Diseases (Vieira M, Kimmitt R and Moon S. F1000Research 2021, 10:190)

“The pneumococcal Advance Market Commitment is an innovative way to make effective and affordable pneumococcal vaccines available for children in developing countries. Through donor commitments, this innovative funding mechanism incentivises vaccine makers to produce suitable and affordable vaccines for the world's poorest countries. These countries are then able to plan for immunisation programmes knowing that vaccines will be available rapidly, in the quantities they need and at affordable prices” (Gavi, 2019).

The Global Antibiotic Research & Development Partnership (GARDP), created in 2016 by the WHO and DNDi, “accelerates the development and access of treatments for drug-resistant infections…Together with essential support from donors and key research and development partnerships, the GARDP global network makes it possible to carry out global research and drug development trials, as well as expand access to antibiotics for appropriate use, in close connection with communities around the world” (GARDP, n.d.).

“The Global Health Investment Corporation was established as an independent not-for-profit corporation whose mission is to mobilize private, public and philanthropic capital to accelerate the development, commercialization and access to products and technologies to improve global health and strengthen global health security…A pioneer of investing in global health, GHIC has been supporting high impact biomedical innovations for nearly a decade. Our inaugural Global Health Investment Fund (GHIF) financed the development of new products to combat urgent public health challenges that disproportionately affect people living in low- and middle-income countries. Building on the success of GHIF, we have expanded our mission to pursue additional partnerships to develop and commercialize health technologies to strengthen global health security” (GHIC, n.d.).

"The Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) was established in August 2009 in collaboration between the Helmholtz Centre for Infection Research (HZI) and the Saarland University." HIPS is the first public health research institute in Germany, constituting of nine research groups and over 220 employees. Their "focus is on the development of novel anti-infectives and the improvement of their applicability to humans (translational research)."